Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Healthcare: 3 Beaten-Up Biotechs -- Are They Buys?

Healthcare: 3 Beaten-Up Biotechs -- Are They Buys?

FromIndustry Focus


Healthcare: 3 Beaten-Up Biotechs -- Are They Buys?

FromIndustry Focus

ratings:
Length:
31 minutes
Released:
Oct 9, 2019
Format:
Podcast episode

Description

Here's why post-approval setbacks have caused Puma Biotechnology, Clovis Oncology, and Regenxbio shares to tumble, and if any of these stocks are finally worth buying. Stocks: PBYI, CLVS, RGNX Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter
Released:
Oct 9, 2019
Format:
Podcast episode

Titles in the series (100)

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.